Blog Category

#BIOEurope: Schnell und Hektisch 
Posted on Nov 12, 2017

  It’s amazing how months of preparation for a conference are realized in 4-5 intense days.¬† From Sunday afternoon until the wee hours of Thursday morning, BIO-Europe in Berlin was jammed with 40 meetings, good meals, a few great receptions, a Buzz Session, two cigarettes, a few glasses of¬†absinthe refreshment, and a new project or

Is the pharmaceutical industry risk averse? 
Posted on Oct 26, 2017

Simple question…is our industry risk averse? Some would say, “Yes, absolutely.” Look at psychiatric drugs, as an example. When the SSRIs were launched in the early 1990s, it was a new era in the treatment of depression and related conditions. Since then, our industry has largely moved away from psychiatry: Richard Friedman, professor of clinical

Generic Drugs: Why Is The Party Ending? 
Posted on Oct 20, 2017

The recent news that Novartis is closing its Colorado-based generics manufacturing facility brought back a few memories. A company spokesperson blamed “above-average pricing pressure“. The products were described as “oral…for a variety of conditions…expensive to make…and no longer competitive. Medicare Part D studies clearly show generic price deflation is quite real, even when some generic

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.